Equilab International and Mayapada Healthcare Group signed Clinical Trial Agreements (CTA) on 4 September for a global phase 3 diabetes study. The trial will take place at Mayapada Hospital Jakarta Selatan and Mayapada Hospital Kuningan. Representatives attending the ceremony included Ronal Simanjuntak, President Director of Equilab International; dr. Dini Handayani, Chief Medical Officer of Mayapada Healthcare Group; and dr. Deasy Sugesty, Director of Mayapada Hospital Kunin

On 5 September 2026, the Indonesian Association for the Study of Medicinals (IASMED) convened its annual meeting to evaluate regulatory developments and strategic priorities for clinical research in Indonesia. The event brought together senior government officials and industry representatives, including the Chairperson of the Indonesian Food and Drug Authority (BPOM) – Prof. dr. Taruna Ikrar, M.Biomed., Ph.D., Director General of Pharmaceuticals and Medical Devices at the Ind

We are pleased to announce that Equilab International has received recognition from the Ministry of Health (MoH) of Iraq as a research centre for Bioequivalence studies, marking another important milestone in strengthening our international regulatory recognition and global presence in Bioequivalence studies. As a leading Bioequivalence Centre in Indonesia and Southeast Asia, this recognition further reflects Equilab’s commitment to maintaining high standards of quality, scie

On 10 September 2026, the Indonesian Food and Drug Authority (BPOM) received a delegation from the Korea National Enterprise for Clinical Trials (KoNECT), Equilab International, and South Korean pharmaceutical companies. Welcomed by BPOM Chairperson – Prof. dr. Taruna Ikrar, M.Biomed., Ph.D., alongside Deputy I for Drug, Narcotics, Psychotropics, Precursors, and Addictive Substances Control – Dr. William Adi Teja, MD., BMed., MMed., and Director of Drug Registration – Dra. Tr

Surabaya, 12 Agustus 2026 – Equilab International, sebagai laboratorium pengujian kosmetik di Indonesia yang telah terakreditasi ISO 17025, berkolaborasi dengan PERKOSMI Jawa Timur dan Kromtekindo dalam penyelenggaraan Seminar Temu Anggota PERKOSMI Jawa Timur yang berlangsung di Mercure Surabaya Grand Mirama dengan mengusung tema “Pemenuhan Klaim dan Standar Mutu Kosmetik di Indonesia”. Seminar ini menjadi wadah bagi para pelaku industri untuk memperkuat pemahaman mengenai kl

Surabaya, 4 Juli 2026 – Equilab International sebagai laboratorium pengujian obat di Indonesia yang sudah terakreditasi ISO 17025 turut berpartisipasi dalam acara RAKERDA HISFARIN Jawa Timur 2026 yang berlangsung di Grand Mercure Novotel Mirama Hotel, Surabaya. RAKERDA HISFARIN Jawa Timur 2026 mengusung tema “Apoteker di Era AI: From Quality Guardian to Data-Driven Decision Maker”. Tujuan Rakerda tahun ini adalah untuk memahami peran apoteker di era AI, khususnya dalam penga

As a leading Contract Research Organization (CRO) in Indonesia and Southeast Asia, Equilab continues to strengthen its role in supporting the development of the research ecosystem in Indonesia, including Clinical Trials, Bioequivalence studies, Dermatology Testing, and Laboratory Testing that meet international quality standards. With over 23 years of experience, Equilab is committed to continuously supporting the development of safe, effective, and high-quality products in I

At the recent CRM Trial Connect 2026 conference, global healthcare leaders highlighted a notable shift in the Asia-Pacific clinical landscape. While Southeast Asia has historically been recognized primarily for its large patient scale, the region is actively improving its "operational efficiency" specifically the speed of trial startup and execution. This progress is changing how global sponsors evaluate the region, turning previous administrative bottlenecks into practical a

Jakarta, 6 Mei 2026 – Equilab International sebagai laboratorium uji kosmetik di Indonesia yang sudah terakreditasi ISO 17025 turut berpartisipasi dalam acara Indonesia Cosmetic Ingredients (ICI) Jakarta 2026 yang berlangsung pada 06 - 08 Mei 2026 di JIEXPO Kemayoran Jakarta. Mengusung tema “Innovating the Future of Cosmetic Ingredients: Technology, Safety, and Sustainable Excellence" ICI Jakarta 2026 menjadi wadah bagi para pelaku industri kosmetik untuk mengeksplorasi inova

Jakarta, 15 April 2026 – Equilab International sebagai laboratorium pengujian obat, pangan, suplemen, dan kosmetik di Indonesia yang sudah terakreditasi ISO 17025 serta telah mendapatkan Rekognisi Maturitas Tingkat 4 dari BPOM turut berpartisipasi dalam acara LAB INDONESIA, Jakarta 2026, yang berlangsung pada 15-17 April 2026 di ICE BSD City. Mengusung tema “Shaping the Future of Indonesia's Laboratory Industry: Innovation, Standards, and Global Competitiveness”, LAB INDONESI

On February 10, 2026, Equilab International and UGM Academic Hospital or also known as Rumah Sakit Akademik Universitas Gadjah Mada (RSA UGM) signed a clinical trial agreement to strengthen clinical trial projects in Indonesia. The agreement was signed by Ronal Simanjuntak, President Director of Equilab International, and Dr. dr. Darwito, S.H., Sp.B(K)On, Director of RSA UGM. This partnership is designed to combine academic clinical excellence with professional study manageme

Equilab International, as a leading Contract Research Organization (CRO) in Indonesia and Southeast Asia, specialized in bioequivalence studies, clinical trial, laboratory testing, and dermatology testing, is proud to be featured in a peer-reviewed article of the Bulletin of the World Health Organization (WHO), one of the world’s most respected global public health journals. The article highlights Equilab’s contribution in scientific laboratory work to support accurate regula